U.S. Hospitality Stock News

NYSE:APAM
NYSE:APAMCapital Markets

Artisan Partners Asset Management (APAM) Net Margin Improvement Challenges Cautious Earnings Narratives

Artisan Partners Asset Management (APAM) closed FY 2025 with fourth quarter revenue of US$335.5 million and basic EPS of US$1.44, while trailing twelve month revenue came in at about US$1.2 billion with EPS of US$4.43. Over the past year, revenue has moved from US$1.11 billion to roughly US$1.2 billion and EPS has shifted from US$3.66 to US$4.43 on a trailing basis, setting a clear earnings benchmark for investors watching the trend. With net profit margin higher than a year ago and headline...
NYSE:COP
NYSE:COPOil and Gas

ConocoPhillips (COP) Valuation Check As Oil Prices Fall On Easing Middle East Tensions

Oil price pullback takes center stage for ConocoPhillips A sharp drop in crude prices after Middle East tensions eased and U.S. Iran talks reduced supply fears has put oil exposure back in focus for ConocoPhillips (COP) and its recent share moves. See our latest analysis for ConocoPhillips. Even with the recent pullback linked to softer crude prices, ConocoPhillips’ share price at US$107.59 reflects strong near term momentum. The 30 day share price return is 8.46% and the 90 day gain is...
NasdaqGS:CYTK
NasdaqGS:CYTKBiotechs

MYQORZO Approval Shifts Cytokinetics Toward Commercial Growth And Valuation Upside

FDA approves MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the U.S. U.S. commercial launch of MYQORZO begins, making the cardiac myosin inhibitor available to eligible patients. Cytokinetics introduces a personalized patient support program to accompany MYQORZO treatment. These developments mark a new product milestone for Cytokinetics, ticker NasdaqGS:CYTK. Cytokinetics, NasdaqGS:CYTK, now has an FDA approved therapy in MYQORZO, adding a commercial...
NasdaqGS:FRSH
NasdaqGS:FRSHSoftware

What Is Freshworks' (FRSH) Investment Narrative?

To own Freshworks, you must believe the company is successfully evolving from a simple help-desk provider into a sophisticated enterprise AI partner. The core bet is that their "Freddy AI" agents will move beyond hype to become an essential, high-margin revenue engine that makes their software indispensable to large corporations, not just small businesses.
NYSE:YUM
NYSE:YUMHospitality

Will Yum’s Pizza Hut Overhaul and Dividend Hike Reshape Yum! Brands' (YUM) Investment Narrative?

Yum! Brands has reported its fourth-quarter and full-year 2025 results, showing higher revenue and net income versus 2024, while the board approved a 6% increase in the quarterly dividend to US$0.75 per share, payable on March 6, 2026 to shareholders of record on February 20, 2026. Alongside strong contributions from Taco Bell and KFC, management launched a review of Pizza Hut that includes closing 250 underperforming U.S. locations and exploring options such as a potential sale, signaling a...